SCHEMBL9622056

SCHEMBL9622056

CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.58
ALDH1A1 P00352 2/20 0.49
LAP3 P28838 3/20 0.47
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.44
FNTA P49354 4/20 0.43
FNTB P49356 4/20 0.43
PGGT1B P53609 3/20 0.43
LTA4H P09960 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9622054 1.00 FOLH1 (0.58) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL13093342 1.00 FOLH1 (0.58) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL30051536 0.97 FOLH1 (0.56) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL30052695 0.96 FOLH1 (0.55) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL30051849 0.94 FOLH1 (0.53) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL17867160 0.93 FOLH1 (0.52) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL17867157 0.93 FOLH1 (0.52) FOLH1ALDH1A1LAP3LMNAMEN1
SCHEMBL30051573 0.93 FOLH1 (0.55) FOLH1LMNAFNTAFNTBPGGT1B
SCHEMBL8012885 0.93 FOLH1 (0.55) FOLH1LMNAFNTAFNTBPGGT1B
SCHEMBL8012892 0.93 FOLH1 (0.55) FOLH1LMNAFNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) 2026-03-12 US claimed
EP-4695413-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF Ohio State Innovation Foundation (US) 2026-02-18 EP claimed
CN-118987163-A Use of sardine peptide-containing composition for improving atopic dermatitis symptoms 海口桥水联合科技有限责任公司 2024-11-22 CN claimed
WO-2024235082-A1 USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS 海口桥水联合科技有限责任公司 2024-11-21 WO claimed
WO-2024216031-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2024-10-17 WO claimed
WO-2024163598-A2 PEPTIDES COMPRISING THIOESTER GROUPS, INCLUDING DEPSIPEPTIDE THIOESTERS, METHODS OF MAKING, AND USE THEREOF BRANDEIS UNIVERSITY (US) 2024-08-08 WO claimed
CN-116350746-B Application of sardine peptide composition in medicines for treating allergic rhinitis 海口桥水联合科技有限责任公司 2024-03-22 CN claimed
US-20230374112-A1 Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof BDC CAPITAL INC. (CA) 2023-11-23 US claimed
CN-116350746-A Application of sardine peptide composition in medicines for treating allergic rhinitis 海口桥水联合科技有限责任公司 2023-06-30 CN claimed
US-20230094471-A1 CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES IMMUNOGEN, INC. (US) 2023-03-30 US claimed
WO-2022067445-A1 BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF CORPORATION GENACOL CANADA INC. (CA) 2022-04-07 WO claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) 2026-03-12 US disclosed
EP-4695413-A1 PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF Ohio State Innovation Foundation (US) 2026-02-18 EP disclosed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
WO-2013086365-A2 BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME METABOLON, INC. (US) 2013-06-13 WO disclosed
WO-2013070962-A1 METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-05-16 WO disclosed
WO-2013070839-A1 BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME METABOLON, INC. (US) 2013-05-16 WO disclosed
EP-0202894-B1 A METHOD FOR DETECTING AMINO ACID DERIVATIVES SEIKO INSTRUMENTS INC. (JP) 1992-02-19 EP disclosed
US-4661443-A FORMATION OF INITIAL NH2-TERMINAL DIPEPTIDES AND TRIPEPTIDES HOFFMANN-LA ROCHE INC. (US) 1987-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP FOLH1 48/4885ALDH1A1 3596/4885LAP3 38/4885
US-20230094471-A1 CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES GABBR2, GABRB1, GABRB2 FOLH1 3658/4885ALDH1A1 1615/4885LAP3 4651/4885
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis VIP, ANPEP, RNPEP FOLH1 274/4885ALDH1A1 4635/4885LAP3 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.